Education
About Us
Working with TipRanks
Follow Us
Modern Chinese Medicine Group Co. Ltd. (HK:1643)
:1643
1643 Stock Chart & Stats
HK$0.51
<HK$0.01(1.54%)
At close: 4:00 PM EST
HK$0.51
<HK$0.01(1.54%)
Day’s Range― - ―
52-Week RangeHK$0.25 - HK$1.17
Previous CloseN/A
Volume456.00K
Average Volume (3M)639.13K
Market Cap
HK$813.60M
Enterprise ValueHK$410.57M
Total Cash (Recent Filing)HK$283.25M
Total Debt (Recent Filing)HK$138.00K
Price to Earnings (P/E)32.9
Beta0.37
Next Earnings
Mar 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding720,000,000
10 Day Avg. Volume382,100
30 Day Avg. Volume639,133
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)0.44
Price to Sales (P/S)0.99
P/FCF Ratio-3.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Low LeverageAn equity ratio near 90% and negligible debt gives long-term financial flexibility: the company can sustain operations during revenue pressure, fund targeted R&D or product development, and pursue opportunistic investments or restructuring without heavy interest burden.
Defensive Industry ExposureOperating in drug manufacturing provides structurally steadier demand and higher barriers to entry vs cyclical sectors. Over the medium term this reduces revenue volatility, supports pricing power for differentiated products, and underpins a baseline of durable cash generation potential.
Reported EPS ImprovementReported EPS growth of ~33% implies improving per-share profitability or capital efficiency. If driven by sustainable cost control or better product mix, sustained EPS gains can replenish retained earnings, enable reinvestment and support recovery in shareholder returns over months.
Bears Say
Zero Operating And Free Cash FlowZero operating and free cash flow in 2024 is a major structural concern: without internal liquidity the firm cannot reliably fund capex, R&D or working capital from operations. That forces dependence on external financing, increasing refinancing and execution risk despite low leverage.
Falling Revenue TrendRevenue declined roughly 16%, which erodes scale economics and pressures long-term margin recovery. Persisting top-line contraction reduces room for R&D and commercial investment, weakens negotiating leverage with suppliers/customers, and makes sustainable turnaround more difficult.
Material Margin And ROE DeteriorationSignificant drops in gross and net margins alongside ROE collapsing to 2% indicate weakening profitability and inefficient capital use. This undermines returns on invested capital, limits reinvestment capacity, and threatens long-term shareholder value unless the company restores margins and operational efficiency.
Modern Chinese Medicine Group Co. Ltd. News
1643 FAQ
What was Modern Chinese Medicine Group Co. Ltd.’s price range in the past 12 months?
Modern Chinese Medicine Group Co. Ltd. lowest stock price was HK$0.24 and its highest was HK$1.17 in the past 12 months.
What is Modern Chinese Medicine Group Co. Ltd.’s market cap?
Modern Chinese Medicine Group Co. Ltd.’s market cap is HK$813.60M.
When is Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date?
Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date is Mar 20, 2026 which is in 25 days.
How were Modern Chinese Medicine Group Co. Ltd.’s earnings last quarter?
Modern Chinese Medicine Group Co. Ltd. released its earnings results on Aug 29, 2025. The company reported HK$0.004 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.004.
Is Modern Chinese Medicine Group Co. Ltd. overvalued?
According to Wall Street analysts Modern Chinese Medicine Group Co. Ltd.’s price is currently Overvalued.
Does Modern Chinese Medicine Group Co. Ltd. pay dividends?
Modern Chinese Medicine Group Co. Ltd. pays a Notavailable dividend of HK$0.017 which represents an annual dividend yield of N/A. See more information on Modern Chinese Medicine Group Co. Ltd. dividends here
What is Modern Chinese Medicine Group Co. Ltd.’s EPS estimate?
Modern Chinese Medicine Group Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modern Chinese Medicine Group Co. Ltd. have?
Modern Chinese Medicine Group Co. Ltd. has 720,000,000 shares outstanding.
What happened to Modern Chinese Medicine Group Co. Ltd.’s price movement after its last earnings report?
Modern Chinese Medicine Group Co. Ltd. reported an EPS of HK$0.004 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.778%.
Which hedge fund is a major shareholder of Modern Chinese Medicine Group Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1643
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Modern Chinese Medicine Group Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.59%
12-Months-Change
Fundamentals
Return on Equity
3.98%
Trailing 12-Months
Asset Growth
8.84%
Trailing 12-Months
Company Description
Modern Chinese Medicine Group Co. Ltd.
Modern Chinese Medicine Group Co., Ltd., an investment holding company, produces and sells proprietary Chinese medicines for elderlies and aged-middle in the People's Republic of China. It offers therapeutics for the qi-deficiency and blood-statis, cardio-cerebrovascular, digestive and gastrointestinal, gynecological, respiratory system, and nervous system conditions. The company was founded in 1986 and is headquartered in Chengde, China. Modern Chinese Medicine Group Co., Ltd. is a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
Technical Analysis
Fusen Pharmaceutical Co., Ltd.
―
China Isotope & Radiation Corp.
―
MicroPort CardioFlow Medtech Corp.
―
Yunkang Group Limited
―
China Shineway Pharmaceutical Group Limited
―